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Abstract
Aims Recent reports have suggested that patients with heart failure (HF) have an altered gut microbiota composition; how-
ever, associations with diet remain largely uninvestigated. We aimed to explore differences in the gut microbiota between pa-
tients with HF with reduced ejection fraction and healthy controls, focusing on associations with diet and disease severity.
Methods and results The microbiota composition of two cross-sectional cohorts (discovery, n = 40 and validation, n = 44) of
patients with systolic HF and healthy controls (n = 266) was characterized by sequencing of the bacterial 16S rRNA gene. The
overall microbial community (beta diversity) differed between patients with HF and healthy controls in both cohorts (P <
0.05). Patients with HF had shifts in the major bacterial phyla, resulting in a lower Firmicutes/Bacteroidetes (F/B) ratio than
controls (P = 0.005). Patients reaching a clinical endpoint (listing for heart transplant or death) had lower bacterial richness
and lower F/B ratio than controls (P < 0.01). Circulating levels of trimethylamine-N-oxide were associated with meat intake
(P = 0.016), but not with gut microbiota alterations in HF. Low bacterial richness and low abundance of several genera in
the Firmicutes phylum were associated with low fibre intake.
Conclusions The gut microbiota in HF was characterized by decreased F/B ratio and reduced bacterial diversity associated with
clinical outcome. The gut microbiota alterations in HF were partly related to low fibre intake, emphasizing the importance of diet
as a covariate in future studies. Our data could provide a rationale for targeting the gut microbiota in HF with high-fibre diet.
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Heart failure (HF) is a major public health issue with increas-
ing prevalence and high mortality and morbidity, at least
partly related to an aging population. Disturbances in meta-
bolic and inflammatory pathways seem to play a role in the
development and progression of HF,1 but the underlying
mechanisms are not completely elucidated. The gut
microbiota, comprising the trillions of bacteria that reside in
the gastrointestinal tract, may influence these pathways.2 In-
deed, host–microbiota interactions likely contribute to sev-
eral diseases even outside the gut,3 including cardiovascular
and metabolic diseases.2
Years ago, it was suggested that the gut–heart axis played
a role in the progression of HF. This theory originally focused
on the decreased mucosal integrity caused by intestinal
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ischaemia or congestion. A compromised mucosal barrier
permits leakage of bacterial products, such as lipopolysac-
charides (a component of the Gram-negative bacterial cell
wall), across the gut wall, resulting in systemic inflamma-
tion.4–6 More recent data suggest that gut microbiota com-
position and function differ between patients with HF and
healthy subjects. Using traditional cultures, Pasini et al. re-
ported an increased abundance of pathogenic bacteria and
fungi in patients with HF,7 while sequencing-based studies
have identified depleted core microbiota, with reduced
abundance of Faecalibacterium as well as functional changes
in the microbiota related to decreased butyrate production
in these patients.8–10
Diet is a crucial modulator of the gut microbiota. Nutrients
can directly interact with colonic components, affecting not
only their abundance but also their growth dynamics.11 Die-
tary residues that enter the colon, such as complex carbohy-
drates (fibre), are substrate for fermentation that produces
short-chain fatty acids. One of the end products of this
microbiota-dependent metabolism is butyrate. Butyrate pro-
vides energy to the gut microbiota and the intestinal epithe-
lium and serves as an important signalling molecule, for
example, by inducing the expansion of colonic regulatory T
cells.12 Another diet-dependent and microbiota-dependent
molecule is trimethylamine-N-oxide (TMAO), which is pro-
duced in the liver from trimethylamine, a by-product of the
microbial metabolism of carnitine and phosphatidylcholine.
TMAO is linked to atherosclerosis, and we and others have
shown that this metabolite is associated with disease severity
in patients with HF.13,14
We have recently shown that the gut microbiota signa-
ture in chronic HF is characterized by large compositional
shifts with low bacterial richness and depletion of bacteria
with butyrate-producing potential.15 The aims of the present
study were to (i) further explore the compositional and
functional differences in the gut microbiota between pa-
tients with HF and healthy controls, including relationships
between the microbiota composition and the aetiology of
HF, and clinical and haemodynamic characteristics; (ii) inves-
tigate associations between dietary habits and the composi-
tion of the gut microbiota; and (iii) examine putative end
products of diet–microbial interactions (TMAO and butyrate)




The study cohort has been briefly described previously.15 We
performed a cross-sectional collection of stool samples from
two independent cohorts (discovery cohort, n = 40 and
validation cohort, n = 44) of patients with HF with reduced
ejection fraction treated at the Department of Cardiology,
Oslo University Hospital Rikshospitalet, Oslo, from July 2014
to December 2016. Healthy controls (n = 266) were randomly
selected from donors registered in the national Norwegian
Bone Marrow Donor Registry (Oslo, Norway) and randomly
allocated to the discovery (n = 133) or validation cohort
(n = 133) for comparison with the respective HF patients.
Follow-up data were available for patients in the discovery
cohort only. Fasting plasma samples and food frequency
questionnaires were available in the validation cohort only,
and diet–microbiota–plasma interactions were therefore
assessed in this cohort alone.
We included patients with stable HF with reduced ejec-
tion fraction according to current HF guidelines16 with
symptoms and signs of HF and a left ventricular (LV) ejec-
tion fraction < 40% as determined by echocardiography
within 15 days prior to inclusion in the study. All patients
included had been stable in New York Heart Association
(NYHA) functional class II–IV at least 6 months prior to in-
clusion. All study patients were on optimal medical therapy
at inclusion. Participants with previous bowel resection, gas-
trointestinal stoma, or self-reported specific diets (e.g.
vegan, vegetarian, and gluten-free and milk-free diets) were
excluded. Patients who had used antibiotics in the 12 weeks
preceding study enrolment were also excluded. Other exclu-
sion criteria were acute coronary syndromes during the last
6 months and significant concomitant disease such as infec-
tion, autoimmune disorders, or malignancy. The patients
were consecutively included in the study. The HF aetiology
was based on disease history, coronary angiography, and
echocardiography and in some cases, also on magnetic res-
onance imaging.
The study was approved by the Regional Committee for
Medical and Health Research Ethics in South-Eastern
Norway and conducted according to the Declaration of Hel-
sinki. Written informed consent was obtained from all
individuals.
Stool sample collection, DNA extraction,
sequencing, and bioinformatics
Stool samples were collected, DNA was extracted, and library
preparations were performed as previously described17 (for
detailed information please see Supplementary Methods in
Supporting Information). Sequencing of the V3–V4 region of
the 16S rRNA gene was performed at the Norwegian Se-
quencing Centre (Oslo, Norway) using the Illumina MiSeq
platform (Illumina, San Diego, California, USA). The Quantita-
tive Insights Into Microbial Ecology version 1.9.1 was used for
post-sequencing processing (more detailed information is
given in the Supplementary Methods in Supporting
Information).
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Food frequency questionnaires
At inclusion, the patients in the validation cohort (n = 37)
completed a self-administrated, validated Norwegian food
frequency questionnaire, aiming to reflect dietary habits over
the past year.18,19 The questionnaire contained around 180
food items, with serving size alternatives specified in house-
hold units and calculated in grams using the software devel-
oped at the Institute for Nutrition Research, University of
Oslo.18
Biochemistry and blood sampling
Routine biochemical parameters were retrieved from hospital
databases. Peripheral venous blood was collected in pyrogen-
free tubes with EDTA as anticoagulant for the measurement
of the levels of TMAO and butyrate (using liquid
chromatography-tandem mass spectrometry) and a gas chro-
matograph equipped with an electron capture detector, re-
spectively). Lipopolysaccharide-binding protein (LBP) and
soluble CD14 (sCD14) were analysed using commercial kits.
For further detailed information, please see Supplementary
Methods in Supporting Information.
Endpoints
The clinical endpoints in this study are all-cause mortality or
listing for heart transplant.
Statistical analysis
The Mann–Whitney U tests or Student’s t-tests were applied
for continuous variables depending on the distribution. Com-
parison of categorical variables was performed using the χ2
test or Fisher’s exact test where appropriate. False discovery
rate was calculated in R according to Benjamini and
Hochberg and denoted as QFDR. All other calculations were
performed in SPSS (V.25; IBM, New York, USA). Clinical end-
points (all-cause mortality or listing for heart transplant)
were only available in the discovery cohort, and dietary data
were only available from the validation cohort. Otherwise,
data from the two HF cohorts were combined for secondary
confirmation of associations between microbiota measure-
ments and clinical characteristics and for binary logistic re-
gression analyses. Circulating metabolites (TMAO and
butyrate) were not normally distributed and were therefore
log-transformed before correlation analyses. For alpha diver-
sity and relative abundances, non-parametric statistics were
applied throughout. Alpha diversity (the bacterial richness
measures Chao1 and observed operational taxonomic units
[OTUs]) and beta diversity (weighted UniFrac) were
calculated in the Quantitative Insights Into Microbial Ecol-
ogy, which was also used when comparing beta diversity
using the permutational ANOVA method. There were no
missing data for the microbiota analyses. In all correlation
analyses, “n” for each analysis is provided.
Results
Participant characteristics
Thirty-six of the patients (43 %) had ischaemic HF, and 48
patients (53%) had non-ischaemic HF (Table 1). Most of
the patients in the non-ischaemic group had dilated cardio-
myopathy (n = 44). The average LV ejection fraction was 26
± 8% in the discovery cohort and 30 ± 6% in the validation
cohort, with corresponding end-diastolic LV volumes 297
(209–355) and 223 (192–266) mL, respectively. Peak tricus-
pid pressure gradient was measured in 60 patients, out of
whom, 31 patients (52%) had a value above 30 mmHg,
taken to represent pulmonary hypertension.20 Furthermore,
52% of the patients had a ratio of the peak early mitral in-
flow velocity to the mitral annular early diastolic velocity
(E/e’) above 15, a surrogate for an elevated LV filling
pressure.
Differences in global microbiota composition and
Firmicutes/Bacteroidetes ratio between patients
with heart failure and controls
In the discovery, as well as in the validation cohort, the global
microbial composition (beta diversity) differed significantly
between patients with HF and healthy controls, although
with considerable overlap between the groups (Figure 1).
The overall difference was driven by the abundances of the
two major phyla Firmicutes and Bacteroidetes. Firmicutes
was less abundant and Bacteroidetes more abundant in
patients with HF. To capture the overall compositional alter-
ations, we calculated a dysbiosis index defined as the
Firmicutes/Bacteroidetes ratio (F/B ratio). Patients with HF
had a lower F/B ratio than controls (Figure 2A–C), and the dif-
ference between patients and controls remained significant
after adjusting for age, gender, and body mass index (BMI)
(P = 0.005).
Firmicutes/Bacteroidetes ratio and bacterial
richness in relation to clinical and haemodynamic
characteristics and clinical outcomes
In the present study, we observed lower bacterial richness
(Figure 3A) and a decreased F/B ratio (Figure 3B) in patients
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who reached this endpoint during follow-up (18 out of 40 pa-
tients in the discovery cohort) (all P values < 0.01). In
Supporting Information, Tables S1–S3, we provide an
overview of associations between markers of comorbidities
and alterations in the microbiota composition and clinical
outcomes. HDL cholesterol was associated with bacterial
Table 1 Characteristics of the study population
Heart failure Healthy controls HF versus HC
n = 84 n = 266 P value
Age (years), median (min–max) 58.9 (39–74) 45.9 (30-61) <0.001
Sex (male patient), n (%) 34 (40.5) 107 (40.2) 1.000
BMI (kg/m2), mean (95% CI) 27.9 (26.8–29.1) 26.4 (25.9-26.9) 0.005
Current smoker, n (%) 28 (33.3) 31 (11.7) <0.001
NYHA class, n (%)
Class II 41 (48.8)
Class III 38 (45.2)
Class IV 5 (6.0)
Ischaemic heart failure, n (%) 36 (42.9)
History of MI, n (%) 32 (38.1)
Hypertension, n (%) 25 (9.8) 11 (4.1) <0.001
Diabetes, n (%) 18 (21.4) 2 (0.8) <0.001
EF (%), mean ± SD 28.2 7.3
LVEDV (mL), median (IQR) 240 (193–304)
CO (L/min), median (IQR) 4.4 (3.7–4.9)
TRG (mmHg), mean ± SD 32 12
NT-proBNP, (ng/L) mean (95% CI) 2664.1 (1726.2–3602.0)
eGFR (mL/min/1.73 m2), mean (95% CI) 68.9 (64.3–73.5)
HbA1c (mmol/mol), mean (95% CI) 6.1 (5.8–6.3)
CRP (mg/L), mean (95% CI) 3.3 (2.3–4.4)
Cholesterol (mmol/L), mean (95% CI) 4.3 (4.0–4.5)
LDL (mmol/L), mean (95% CI) 2.6 (2.4–2.8)
HDL (mmol/L), mean (95% CI) 1.3 (1.2–1.4)
Medication, n (%)
ACEi/ARB 80 (95.2) 10 (3.8) <0.001
Beta blocker 81 (96.4) 2 (0.8) <0.001
Diuretics 69 (82.1)
Statins 52 (61.9) 11 (4.1) <0.001
Digoxin 5 (6.0)
Oral anticoagulation 42 (50.0)
Calcium antagonists 2 (2.4)
Insulin 10 (11.9)
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; CO, cardiac output; CRP, C-
reactive protein; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; IQR, inter quartile range;
LDL, low-density lipoprotein; LVEDV, left ventricular end-diastolic volume; MI, myocardial infarction; NT-proBNP, N-terminal pro B-type
natriuretic peptide; NYHA, New York Heart Association; SD, standard deviation; TRG, peak tricuspid regurgitation gradient.
Figure 1 Overall microbial community differed between heart failure patients (HF) and controls.Beta diversity plot (weighted UniFrac) showing differ-
ences in the overall bacterial community of HF patients and healthy controls (pseudo-F statistic for discovery, validation, and combined cohort: 2.2 [P =
0.042], 2.5 [P = 0.024], and 4.1 [P = 0.002], respectively). The percentage on the axis of the principal component analysis plot in the combined cohort
corresponds to the percentage of variance explained by each axis.
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richness (Chao 1) but not with clinical endpoints. There was a
numerically higher proportion of non-ischaemic cardiomyop-
athy among the patients who died or were listed for
heart transplant (13 out of 18 patients) than in patients
who did not meet this endpoint (35 out of 66 patients, P
for difference = 0.14).
There were no significant correlations between the
dysbiosis index (F/B ratio) and sex, age, or smoking status
(Supporting Information, Table S4). Furthermore, we did
not observe any associations between the dysbiosis index
and NYHA class, N-terminal pro B-type natriuretic peptide
(NT-proBNP), cardiac output, LV ejection fraction, LV end-
diastolic volume, or the peak tricuspid regurgitation gradient
(Table 2).
Associations between the aetiology of heart
failure and the Firmicutes/Bacteroidetes-ratio
and bacterial richness
We next explored whether gut microbiota alterations were as-
sociated with HF aetiology. The F/B ratio was higher in healthy
controls than in patients with ischaemic HF (P < 0.05) and in
patients with non-ischaemic HF (P < 0.01) (Figure 2D). The
F/B ratio was numerically higher in patients with ischaemic
HF than in patients with non-ischaemic HF, but this difference
was not significant. Compared with healthy controls, patients
with non-ischaemic HF (n = 44) had a significantly lower ob-
served OTUs and lower Chao1 index, both of which are mea-
sures of bacterial richness (Figure 4).
Figure 2 Large shifts in bacterial composition in heart failure (HF) patients.There was a significant reduction in the Firmicutes/Bacteroidetes ratio (F/B
ratio) in both the (A) discovery, (B) validation, and (C) the combined cohort. (D) When stratifying the combined cohort of heart failure patients accord-
ing to HF aetiology, healthy controls had a higher F/B ratio than patients with ischaemic HF and non-ischaemic HF. The ratio was numerically higher in
patients with ischaemic than in non-ischaemic HF. Data shown as median and interquartile range. *P < 0.05, **P < 0.01, ***P < 0.001.
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The gut microbiota composition and
intraindividual diversity in association with fibre
intake
Table 3 shows associations between bacterial richness, HF-
related dysbiosis (F/B ratio and the 15 genera differing be-
tween HF patients and controls), and fibre intake. Both Chao1
and observed OTUs correlated with fibre intake (Spearman’s
rho 0.38, P = 0.018; Spearman s rho 0.34, P = 0.039). Further-
more, the abundance of Fusicatenibacter, Lachnospiraceae
FCS020, Lachnospiraceae ND3007, and Anaerostipes, several
of which are known butyrate producers, correlated to fibre
intake (Table 3).
Relationship between the gut microbiota
composition, diet-dependent and
microbiota-dependent metabolites in plasma
Given the relationship between fibre intake and butyrate-
producing genera in patients with HF, we also analysed the
relationships between circulating butyrate, diet, and HF-
associated gut microbiota characteristics, without detecting
any significant correlations (Table 4). As butyrate is a nutrient
for colonocytes and important for gut barrier function, we
also measured markers of gut leakage, LBP, and subsequent
monocyte activation, sCD14. However, except for moderate
negative correlations between sCD14 and Bifidobacterium
(rho = 0.27, P = 0.014) and between LBP and
Lachnospiracea NC2004 (rho = 0.27, P = 0.014), gut leakage
and monocyte activation markers did not correlate with HF-
associated gut microbiota alterations (Supporting Informa-
tion, Table S5).
In contrast to the intake of dietary fibre, meat intake and
energy intake were not correlated with HF-associated gut
microbiota characteristics (data not shown). As for the
microbiota-dependent metabolite TMAO, there was a signifi-
cant correlation with meat intake (r = 0.39, P = 0.016), but no
association between TMAO levels and microbiota changes as-
sociated with HF. Energy intake and relative contribution
from different dietary components are given in Supporting In-
formation, Table S6.
Figure 3 Depletion of bacteria in heart failure (HF) patients reaching an endpoint during follow-up.(A) There was a trend to decreasing measure of
bacterial richness and clinical progression. (B) Patients with endpoint also showed lower Firmicutes/Bacteroidetes-ratio (F/B ratio) compared with
healthy controls, in contrast to HF patients without endpoint during follow-up. Data in (A) shown as mean and 95% confidence interval, data in (B)
shown as median and interquartile range. HTx, listing for heart transplant; NS, not significant; OTU, operational taxonomic units.
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We have previously reported data from this study population,
consisting of two cohorts comprising a total of 84 well-
treated patients with HF and 266 control subjects, showing
that the gut microbiota composition differed considerably be-
tween patients and controls.15 In the present study, we ex-
tended these findings to show that (i) the overall microbial
community (beta diversity) differed between HF patients
and controls; (ii) patients with HF had a lower abundance of
bacteria in the Firmicutes phylum and a higher abundance
of Bacteroidetes (a decreased F/B ratio); (iii) patients who
reached an endpoint during follow-up (listing for heart trans-
plantation or all-cause mortality) had lower bacterial richness
and F/B ratio; and (iv) a lower fibre intake correlated with
dysbiosis in HF, including a lower bacterial richness and a
lower abundance of four of the bacterial genera that were re-
duced in HF.
We found an increased abundance of microbes belonging
to the phylum Bacteroidetes and a lower abundance of
Firmicutes, and that a low F/B ratio was associated with a
poor prognosis in HF. Altered F/B ratio has previously been
observed in other diseases, e.g., type 2 diabetes21 and obe-
sity.22 Of note, we found no association between the F/B ra-
tio and BMI, and the difference between patients and
controls remained significant after adjusting for age, gender,
and BMI.
Taken together with contemporary studies from Japan,
China, and Germany,8–10 our results firmly establish that the
gut microbiota is altered in patients with HF. A common find-
ing in these studies is the relative reduction in taxa from the
Table 3 Correlations between alpha diversity, Firmicutes/
Bacteroidetes-ratio and differentiating bacterial taxa, and fibre in-
take in heart failure patients
Fibre intake (g/day) n = 37
rho P value
Chao1 0.386 0.018
Observed OTUs 0.341 0.039
FB-ratio 0.186 0.271
Uncultured bacterium 0.078 0.648





Lachnospiraceae NC2004 0.322 0.052
Lachnospiraceae FCS020 0.373 0.023
Pseudobutyrivibrio 0.058 0.732
Lachnospiraceae ND3007 0.393 0.016
Blautia 0.074 0.662
Anaerostipes 0.473 0.003
Eubacterium hallii group 0.037 0.829
Coprococcus (3) 0.125 0.461
Faecalibacterium 0.208 0.216
Correlations between alpha diversity (Chao1 and observed OTUs),
Firmicutes/Bacteroidetes-ratio, and differentiating bacterial taxa
and fibre intake in heart failure patients. Orange colored taxa are
high, while blue colored taxa are low in patients with heart failure
compared with healthy controls.
B, Bacteroidetes; F, Firmicutes; OTUs, operational taxonomic units.
Spearman’s rank correlations were performed.
P values < 0.05 in bold.
Table 4
TMAO n = 37 Butyrate n = 37
r P value r P value
Fibre intake (g/day) 0.075 0.660 0.197 0.242
Meat intake (g/day) 0.393* 0.016 0.092 0.587
Energy intake (kJ/day) 0.087 0.609 0.235 0.161
Correlations with (log-transformed) plasma metabolites are given
as Pearsons r with P values < 0.05 in bold. TMAO,
Trimethylamine-N-oxide. Correlations between the daily intake of
dietary fibre, meat and energy, and the microbiota-dependent me-
tabolites TMAO and butyrate
Figure 4 Gut bacterial richness is reduced in non-ischaemic heart failure patients (HF).Non-ischaemic HF showed significantly decreased number of
observed OTUs compared with healthy controls, in contrast to ischaemic HF, while both groups showed decreased Chao1 index. Data shown as mean
and 95% confidence interval. NS, not significant; OTU, operational taxonomic unit. *P < 0.05, **P < 0.01.
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Lachnospiracea or Ruminococcacea family (both belonging to
the Firmicutes phylum), known for their capacity of produc-
ing the short-chain fatty acid butyrate. However, a limitation
of the studies published so far is the lack of dietary data. A
novel aspect of the present study was the prospective, struc-
tured characterization of the patients’ diet in the validation
cohort. Fibre intake was positively correlated with microbial
diversity and with the abundance of some of the genera in
the Firmicutes phylum that are altered in HF, including sev-
eral microbes from the Lachnospiracea family with capacity
to metabolize fibre into butyrate.
Butyrate serves as the main energy source for colonocytes,
exerts local anti-inflammatory effects in the gut wall, and has
an important role in maintaining the gut barrier,23 although
we could not detect any association between HF-related
dysbiosis and markers of gut leakage, with the exception of
a weak negative correlation between LBP and Lachnospiracea
NC2004. However, in a previous paper from this cohort, we
found an association between several genera of the
Lachnospiracea family and a marker of T cell activation, par-
ticularly in patients reaching a clinical endpoint.17 High
amounts of dietary fibre intake have been previously re-
ported to significantly reduce incidence and mortality from
cardiovascular disease.24 Taken together, our two studies
from the present cohort could imply that a reduced fibre in-
take and, in consequence, a diminished bacterial production
of butyrate could represent a link between diet, gut microbi-
ota alterations, and low-grade inflammation with potential
relevance for progression of HF. However, markers of gut
leakage did not correlate to a large degree with HF-related
gut microbiota alterations.
In line with our findings, a recent study showed that total
fibre intake was significantly associated with overall microbial
community composition in 76 presumably healthy individ-
uals.25 Although associations between dietary fibre and mi-
crobiota composition are not unique to HF, it is striking that
some of the dysbiosis observed in HF is related to low fibre
intake. However, the lack of dietary data in the control group
prevents us from adjusting HF-related dysbiosis for fibre in-
take, which is a clear limitation of our study. Furthermore, di-
etary data could be a major confounder also in previous
microbiota studies and should be included when planning fu-
ture studies. Our finding, if confirmed, could potentially even
provide a rationale for targeting the gut microbiome with
high-fibre diet in HF patients.
The diet-dependent and microbiota-dependent metabolite
TMAO has in many studies been associated with cardiovascu-
lar disease.13,14 However, none of the published microbiome
studies in HF8–10 have so far reported data on TMAO in asso-
ciation to HF-related microbiota alterations. Of note, we
found no association between TMAO levels and HF-related
dysbiosis. In contrast, TMAO was associated with meat in-
take, probably reflecting that meat, in addition to other die-
tary sources is a major contributor to the generation of the
TMAO precursor trimethylamine, which is generated by mi-
crobial conversion of dietary choline, phosphatidylcholine,
and carnitine.26 These results confirm the findings of a recent
crossover study, which demonstrated an association between
red meat and raised TMAO levels.27 Our data suggest that
TMAO is more related to dietary patterns than to microbiota
alterations in HF, again emphasizing the importance of includ-
ing dietary data in microbiota-related studies.
We found no association between the gut microbiota com-
position and cardiac function as measured by echocardiogra-
phy, NT-proBNP, and NYHA functional class. Nevertheless,
some of the alterations in the gut microbiota were associated
with an adverse outcome. Hence, our findings challenge the
view that the altered gut microbiota in HF is merely a conse-
quence of congestion and intestinal ischaemia,28 although we
did not investigate intestinal congestion per se. Our findings,
in light of other recently published studies8–10,15 could
suggest an independent role for the gut microbiota in the
progression of HF, not directly related to haemodynamic
changes, and that the changes are not just a reflection of
HF severity.
Of potential importance, the HF-related dysbiosis seemed
to be particularly pronounced in patients with a non-
ischaemic aetiology. Although the present study did not
have sufficient power to detect significant differences be-
tween ischaemic and non-ischaemic HF, our findings could
indicate that the HF-related dysbiosis is not merely a reflec-
tion of atherosclerosis. Most of the patients with a non-
ischaemic aetiology had idiopathic dilated cardiomyopathy,
where metabolic signatures have been proposed to be al-
tered by the microbiome, although knowledge is so far
sparse.29 In light of our findings, we propose that gut micro-
biota alterations should be investigated as a potentially con-
tributing or aggravating factor in these patients. Adequately
powered studies with multiomic analyses (genomics,
metagenomics, proteomics, metabolomics) could be impor-
tant first steps for identifying relevant pathways in this
group of HF patients.
Our study has some limitations. As this study is associative
by nature, we cannot state any causal relationship in the re-
sults that we found. A cause–effect relationship would have
to be shown in a prospective controlled study. Patients’ diet
was neither controlled nor monitored, making it a relevant
confounder, and food frequency questionnaires were self-
reported. Cases and controls were not perfectly matched.
The younger age of the controls may explain differences in di-
versity measures. However, the main results of the present
study were robust to multivariable regressions, and microbial
diversity does not necessarily decrease with age.30 The study
size is moderate, increasing the risk of not detecting true dif-
ferences among less frequent microbes. In particular, the
number of clinical endpoints was low, and follow-up data
should be regarded as exploratory. There are also differences
in disease severity between the two cohorts of HF patients
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that could affect our ability to discover relevant associations.
However, differences found in both cohorts following a two-
stage strategy should contribute to the robustness of the
main findings in this study.
In summary, our study an altered gut microbiota composi-
tion in patients with chronic, systolic HF, mostly driven by
changes in the two major phyla Firmicutes and Bacteroidetes,
resulting in a decreased F/B ratio. These changes were to
some degree associated with aetiology and clinical outcomes.
Of note, the compositional changes and the reduced micro-
bial richness were partly associated with a reduced fibre in-
take. Thus, dietary patterns should be included in future
studies, both as covariates and potential treatment targets.
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